LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
56.37
+0.92 (1.66%)
Aug 29, 2025, 4:00 PM - Market closed
LivaNova Revenue
LivaNova had revenue of $352.52M in the quarter ending June 30, 2025, with 10.66% growth. This brings the company's revenue in the last twelve months to $1.31B, up 8.23% year-over-year. In the year 2024, LivaNova had annual revenue of $1.25B with 8.66% growth.
Revenue (ttm)
$1.31B
Revenue Growth
+8.23%
P/S Ratio
2.34
Revenue / Employee
$451,493
Employees
2,900
Market Cap
3.08B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.25B | 99.89M | 8.66% |
Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
Dec 31, 2021 | 1.04B | 101.12M | 10.82% |
Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
LIVN News
- 7 days ago - LivaNova to Host Investor Day on November 12, 2025 - Business Wire
- 10 days ago - LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September - Business Wire
- 14 days ago - LivaNova Launches Essenz Perfusion System in China - Business Wire
- 25 days ago - LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance - Business Wire
- 7 weeks ago - LivaNova to Announce Second-Quarter 2025 Results - Business Wire
- 2 months ago - LivaNova: The Sell-Off Is Excessive Here - Seeking Alpha
- 3 months ago - CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy - Business Wire